A Phase I Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma
What is the purpose of this trial?
This study is a Phase 1, open-label, single institution, dose escalation and dose expansion study to evaluate the efficacy, safety, and tolerability of APX005M in combination with nivolumab and ipilimumab in patients with advanced melanoma and RCC.
- Trial withYale Cancer Center
- Start Date05/16/2022
- End Date08/31/2024
- Last Updated05/20/2022
- Study HIC#2000026830